Advancements in Small Molecule PROTACs Containing Indole/Spiro-fused Oxindole Scaffolds: An Emerging Degrader Targeting Cancers

  • Authors: Li X.1, Liu Y.2, Huang W.1, Xie X.3, Zhu H.4, Peng C.1, Han B.1
  • Affiliations:
    1. State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology, Chengdu University of Traditional Chinese Medicine
    2. State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology,, Chengdu University of Traditional Chinese Medicine
    3. State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology,, Chengdu University of Traditional Chinese Medicine,
    4. Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University,
  • Issue: Vol 23, No 10 (2023)
  • Pages: 1164-1173
  • Section: Oncology
  • URL: https://filvestnik.nvsu.ru/1871-5206/article/view/694286
  • DOI: https://doi.org/10.2174/1871520622666220509175305
  • ID: 694286

Cite item

Full Text

Abstract

:Indole and spiro-fused oxindole frameworks widely exist in a variety of natural bioactive products, pharmaceuticals, and drug candidates, featuring unique functions in the regulation of proliferation, infiltration, and metastasis of cancer cells. In recent years, significant progress in proteolysis targeting chimeric (PROTAC) technology that employs ubiquitin-proteasome system (UPS) to eliminate disease-associated proteins has been witnessed, thus opening a promising avenue to the discovery of new indole-related drugs.

:In this review, we focus on summarizing the achievements of small molecule PROTACs that involve indole/spirofused oxindole scaffolds in the part of ligands of the protein of interest (POI). Current challenges and future directions in this promising field are discussed at the end of this review. For the convenience of readers, our review is divided into five parts according to the types of target proteins. We hope this review could bring a quick look and some inspiration to researchers in relevant fields.

About the authors

Xiang Li

State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Yanqing Liu

State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology,, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Wei Huang

State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Xin Xie

State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology,, Chengdu University of Traditional Chinese Medicine,

Email: info@benthamscience.net

Hongping Zhu

Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University,

Email: info@benthamscience.net

Cheng Peng

State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology, Chengdu University of Traditional Chinese Medicine

Author for correspondence.
Email: info@benthamscience.net

Bo Han

State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Pharmacy and College of Medical Technology, Chengdu University of Traditional Chinese Medicine

Author for correspondence.
Email: info@benthamscience.net

References

  1. Ruiz-Sanchis, P.; Savina, S.A.; Albericio, F.; Alvarez, M. Structure, Bioactivity and Synthesis of Natural Products with Hexahydropyrrolo2,3-b indole. Chem. - Eur. J., 2011, 17(5), 1388-1408. doi: 10.1002/chem.201001451 PMID: 21268138
  2. Zhang, M.Z.; Chen, Q.; Yang, G.F. A review on recent developments of indole-containing antiviral agents. Eur. J. Med. Chem., 2015, 89, 421-441. doi: 10.1016/j.ejmech.2014.10.065 PMID: 25462257
  3. Sidhu, J.S.; Singla, R. Mayank; Jaitak, V. Indole derivatives as anticancer agents for breast cancer therapy: A Review. Anticancer. Agents Med. Chem., 2015, 16(2), 160-173. doi: 10.2174/1871520615666150520144217 PMID: 25991424
  4. Zhao, Q.; Peng, C.; Zheng, C.; He, X-H.; Huang, W.; Han, B. Recent advances in characterizing natural products that regulate autophagy. Anticancer. Agents Med. Chem., 2019, 19(18), 2177-2196. doi: 10.2174/1871520619666191015104458 PMID: 31749434
  5. Zheng, C.; You, S.L. Catalytic asymmetric dearomatization (CADA) reaction-enabled total synthesis of indole-based natural products. Nat. Prod. Rep., 2019, 36(11), 1589-1605. doi: 10.1039/C8NP00098K PMID: 30839047
  6. Devi, N.; Kaur, K.; Biharee, A.; Jaitak, V. Recent development in Indole derivatives as anticancer agent: Amechanistic approach. Anticancer. Agents Med. Chem., 2021, 21(14), 1802-1824. doi: 10.2174/1871520621999210104192644 PMID: 33397272
  7. Chen, F.Y.; Li, X.; Zhu, H.P.; Huang, W. Regulation of the Ras-related signaling pathway by small molecules containing an indole core scaffold: A potential antitumor therapy. Front. Pharmacol., 2020, 11, 280. doi: 10.3389/fphar.2020.00280 PMID: 32231571
  8. Han, B.; He, X.H.; Liu, Y.Q.; He, G.; Peng, C.; Li, J.L. Asymmetric organocatalysis: An enabling technology for medicinal chemistry. Chem. Soc. Rev., 2021, 50(3), 1522-1586. doi: 10.1039/D0CS00196A PMID: 33496291
  9. Chadha, N.; Silakari, O. Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view. Eur. J. Med. Chem., 2017, 134, 159-184. doi: 10.1016/j.ejmech.2017.04.003 PMID: 28412530
  10. Dadashpour, S.; Emami, S. Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms. Eur. J. Med. Chem., 2018, 150, 9-29. doi: 10.1016/j.ejmech.2018.02.065 PMID: 29505935
  11. Wan, Y.; Li, Y.; Yan, C.; Yan, M.; Tang, Z. Indole: A privileged scaffold for the design of anti-cancer agents. Eur. J. Med. Chem., 2019, 183111691 doi: 10.1016/j.ejmech.2019.111691 PMID: 31536895
  12. Zhu, H.; Li, Y.; Liu, Y.; Han, B. Bivalent SMAC mimetics for treating cancer by antagonizing inhibitor of apoptosis proteins. ChemMedChem, 2019, 14(23), 1951-1962. doi: 10.1002/cmdc.201900410 PMID: 31692274
  13. Wang, B.; Peng, F.; Huang, W.; Zhou, J.; Zhang, N.; Sheng, J.; Haruehanroengra, P.; He, G.; Han, B. Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma. Acta Pharm. Sin. B, 2020, 10(8), 1492-1510. doi: 10.1016/j.apsb.2019.12.013 PMID: 32963945
  14. Zhang, X.; Li, X.; Li, J-L.; Wang, Q-W.; Zou, W-L.; Liu, Y-Q.; Jia, Z-Q.; Peng, F.; Han, B. Regiodivergent construction of medium-sized heterocycles from vinylethylene carbonates and allylidenemalononitriles. Chem. Sci. (Camb.), 2020, 11(11), 2888-2894. doi: 10.1039/C9SC06377C PMID: 34122789
  15. Crom, W.R.; de Graaf, S.S.; Synold, T.; Uges, D.R.; Bloemhof, H.; Rivera, G.; Christensen, M.L.; Mahmoud, H.; Evans, W.E. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J. Pediatr., 1994, 125(4), 642-649. doi: 10.1016/S0022-3476(94)70027-3 PMID: 7931891
  16. Meschini, S.; Marra, M.; Condello, M.; Calcabrini, A.; Federici, E.; Dupuis, M.L.; Cianfriglia, M.; Arancia, G. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells. Int. J. Oncol., 2005, 27(6), 1597-1603. PMID: 16273216
  17. Wang, S.; Sun, W.; Zhao, Y.; McEachern, D.; Meaux, I.; Barrière, C.; Stuckey, J.A.; Meagher, J.L.; Bai, L.; Liu, L.; Hoffman-Luca, C.G.; Lu, J.; Shangary, S.; Yu, S.; Bernard, D.; Aguilar, A.; Dos-Santos, O.; Besret, L.; Guerif, S.; Pannier, P.; Gorge-Bernat, D.; Debussche, L. SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res., 2014, 74(20), 5855-5865. doi: 10.1158/0008-5472.CAN-14-0799 PMID: 25145672
  18. Oxnard, G.R.; Hu, Y.; Mileham, K.F.; Husain, H.; Costa, D.B.; Tracy, P.; Feeney, N.; Sholl, L.M.; Dahlberg, S.E.; Redig, A.J.; Kwiatkowski, D.J.; Rabin, M.S.; Paweletz, C.P.; Thress, K.S.; Jänne, P.A. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib. JAMA Oncol., 2018, 4(11), 1527-1534. doi: 10.1001/jamaoncol.2018.2969 PMID: 30073261
  19. McKeage, K. Alectinib: A review of its use in advanced ALK-rearranged non-small cell lung cancer. Drugs, 2015, 75(1), 75-82. doi: 10.1007/s40265-014-0329-y PMID: 25428710
  20. Ricci, S.; Antonuzzo, A.; Galli, L.; Ferdeghini, M.; Bodei, L.; Orlandini, C.; Conte, P.F. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann. Oncol., 2000, 11(9), 1127-1130. doi: 10.1023/A:1008383132024 PMID: 11061606
  21. Broder, M.S.; Beenhouwer, D.; Strosberg, J.R.; Neary, M.P.; Cherepanov, D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J. Gastroenterol., 2015, 21(6), 1945-1955. doi: 10.3748/wjg.v21.i6.1945 PMID: 25684964
  22. Chu, E.; Sartorelli, A. Cancer chemotherapy. Basic Clin. Pharmacol., 2004, 9, 898-930.
  23. Chabner, B.A.; Longo, D.L. Cancer chemotherapy and biotherapy: Principles and practice; Lippincott Williams & Wilkins, 2011.
  24. Wang, Z.; Sun, H.; Yakisich, J.S. Overcoming the blood-brain barrier for chemotherapy: Limitations, challenges and rising problems. Anticancer. Agents Med. Chem., 2014, 14(8), 1085-1093. doi: 10.2174/18715206113139990029 PMID: 23092271
  25. El-Hussein, A.; Manoto, S.L.; Ombinda-Lemboumba, S.; Alrowaili, Z.A.; Mthunzi-Kufa, P. A review of chemotherapy and photodynamic therapy for lung cancer treatment. Anticancer. Agents Med. Chem., 2021, 21(2), 149-161. doi: 10.2174/1871520620666200403144945 PMID: 32242788
  26. Li, X.; Zhang, C.T.; Ma, W.; Xie, X.; Huang, Q. Oridonin: A review of its pharmacology, pharmacokinetics and toxicity. Front. Pharmacol., 2021, 12645824 doi: 10.3389/fphar.2021.645824 PMID: 34295243
  27. Wilson, W.R.; Hay, M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer, 2011, 11(6), 393-410. doi: 10.1038/nrc3064 PMID: 21606941
  28. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer, 2013, 13(10), 714-726. doi: 10.1038/nrc3599 PMID: 24060863
  29. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: An overview. Cancers (Basel), 2014, 6(3), 1769-1792. doi: 10.3390/cancers6031769 PMID: 25198391
  30. Sun, T.M.; Zhang, Y.S.; Pang, B.; Hyun, D.C.; Yang, M.X.; Xia, Y.N. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed., 2014, 53(46), 12320-12364.
  31. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science, 2015, 348(6230), 56-61. PMID: 25838373
  32. Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell, 2015, 161(2), 205-214. doi: 10.1016/j.cell.2015.03.030 PMID: 25860605
  33. Bhan, A.; Soleimani, M.; Mandal, S.S. Long noncoding RNA and cancer: A new paradigm. Cancer Res., 2017, 77(15), 3965-3981. doi: 10.1158/0008-5472.CAN-16-2634 PMID: 28701486
  34. Hirsch, F.R.; Scagliotti, G.V.; Mulshine, J.L.; Kwon, R.; Curran, W.J., Jr; Wu, Y.L.; Paz-Ares, L. Lung cancer: Current therapies and new targeted treatments. Lancet, 2017, 389(10066), 299-311. doi: 10.1016/S0140-6736(16)30958-8 PMID: 27574741
  35. Singh, T.P.; Singh, O.M. Recent progress in biological activities of indole and indole alkaloids. Mini Rev. Med. Chem., 2018, 18(1), 9-25. PMID: 28782480
  36. Cairns, R.A.; Harris, I.S.; Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer, 2011, 11(2), 85-95. doi: 10.1038/nrc2981 PMID: 21258394
  37. Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. Nature, 2011, 480(7378), 480-489. doi: 10.1038/nature10673 PMID: 22193102
  38. Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A., Jr; Kinzler, K.W. Cancer genome landscapes. Science, 2013, 339(6127), 1546-1558. doi: 10.1126/science.1235122 PMID: 23539594
  39. Lee, J.; Xu, Y.; Zhang, T.; Cui, L.; Saidi, L.; Ye, Y. Secretion of misfolded cytosolic proteins from mammalian cells is independent of chaperone-mediated autophagy. J. Biol. Chem., 2018, 293(37), 14359-14370. doi: 10.1074/jbc.RA118.003660 PMID: 30072379
  40. Schneider, K.L.; Nyström, T.; Widlund, P.O. Studying spatial protein quality control, proteopathies, and aging using different model misfolding proteins in S. Cerevisiae. Front. Mol. Neurosci., 2018, 11, 249. doi: 10.3389/fnmol.2018.00249 PMID: 30083092
  41. Ciechanover, A.; Kwon, Y.T. Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies. Exp. Mol. Med., 2015, 47(3), e147-e147. doi: 10.1038/emm.2014.117 PMID: 25766616
  42. Lai, A.C.; Crews, C.M. Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov., 2017, 16(2), 101-114. doi: 10.1038/nrd.2016.211 PMID: 27885283
  43. Dissmeyer, N.; Rivas, S.; Graciet, E. Life and death of proteins after protease cleavage: Protein degradation by the N-end rule pathway. New Phytol., 2018, 218(3), 929-935. doi: 10.1111/nph.14619 PMID: 28581033
  44. Wu, S-Y.; Lan, S-H.; Wu, S-R.; Chiu, Y-C.; Lin, X-Z.; Su, I-J.; Tsai, T-F.; Yen, C-J.; Lu, T-H.; Liang, F-W.; Li, C-Y.; Su, H-J.; Su, C-L.; Liu, H-S. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology, 2018, 68(1), 141-154. doi: 10.1002/hep.29781 PMID: 29328502
  45. Karlgren, M.; Simoff, I.; Keiser, M.; Oswald, S.; Artursson, P. CRISPR-Cas9: A new addition to the drug metabolism and disposition tool box. Drug Metab. Dispos., 2018, 46(11), 1776-1786. doi: 10.1124/dmd.118.082842 PMID: 30126863
  46. Neklesa, T.K.; Winkler, J.D.; Crews, C.M. Targeted protein degradation by PROTACs. Pharmacol. Ther., 2017, 174, 138-144. doi: 10.1016/j.pharmthera.2017.02.027 PMID: 28223226
  47. An, S.; Fu, L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine, 2018, 36, 553-562. doi: 10.1016/j.ebiom.2018.09.005 PMID: 30224312
  48. Bao, S-M.; Hu, Q-H.; Yang, W-T.; Wang, Y.; Tong, Y-P.; Bao, W-D. Targeting epidermal growth factor receptor in non-small-cell-lung cancer: Current state and future perspective. Anticancer. Agents Med. Chem., 2019, 19(8), 984-991. doi: 10.2174/1871520619666190313161009 PMID: 30868964
  49. Paiva, S.L.; Crews, C.M. Targeted protein degradation: Elements of PROTAC design. Curr. Opin. Chem. Biol., 2019, 50, 111-119. doi: 10.1016/j.cbpa.2019.02.022 PMID: 31004963
  50. Burslem, G.M.; Crews, C.M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell, 2020, 181(1), 102-114. doi: 10.1016/j.cell.2019.11.031 PMID: 31955850
  51. Ding, Y.; Fei, Y.; Lu, B. Emerging new concepts of degrader technologies. Trends Pharmacol. Sci., 2020, 41(7), 464-474. doi: 10.1016/j.tips.2020.04.005 PMID: 32416934
  52. Wang, Y.; Jiang, X.; Feng, F.; Liu, W.; Sun, H. Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B, 2020, 10(2), 207-238. doi: 10.1016/j.apsb.2019.08.001 PMID: 32082969
  53. Martín-Acosta, P.; Xiao, X. PROTACs to address the challenges facing small molecule inhibitors. Eur. J. Med. Chem., 2021, 210112993 doi: 10.1016/j.ejmech.2020.112993 PMID: 33189436
  54. Huang, X.; Dixit, V.M. Drugging the undruggables: Exploring the ubiquitin system for drug development. Cell Res., 2016, 26(4), 484-498. doi: 10.1038/cr.2016.31 PMID: 27002218
  55. Schlesiger, S.; Toure, M.; Wilke, K.E.; Huck, B.R. Accelerating the discovery of next-generation small-molecule protein degraders. Aldrichim Acta, 2019, 52(2), 35-49.
  56. Sakamoto, K.M.; Kim, K.B.; Kumagai, A.; Mercurio, F.; Crews, C.M.; Deshaies, R.J. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8554-8559. doi: 10.1073/pnas.141230798 PMID: 11438690
  57. Sakamoto, K.M.; Kim, K.B.; Verma, R.; Ransick, A.; Stein, B.; Crews, C.M.; Deshaies, R.J. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. Proteomics, 2003, 2(12), 1350-1358. doi: 10.1074/mcp.T300009-MCP200 PMID: 14525958
  58. Li, X.; Song, Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J. Hematol. Oncol., 2020, 13(1), 50. doi: 10.1186/s13045-020-00885-3 PMID: 32404196
  59. Liu, J.; Chen, H.; Ma, L.; He, Z.; Wang, D.; Liu, Y.; Lin, Q.; Zhang, T.; Gray, N.; Kaniskan, H.U.; Jin, J.; Wei, W. Light-induced control of protein destruction by opto-PROTAC. Sci. Adv., 2020, 6(8)eaay5154 doi: 10.1126/sciadv.aay5154 PMID: 32128407
  60. Wade, M.; Li, Y-C.; Wahl, G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer, 2013, 13(2), 83-96. doi: 10.1038/nrc3430 PMID: 23303139
  61. Li, Y.; Yang, J.; Aguilar, A.; McEachern, D.; Przybranowski, S.; Liu, L.; Yang, C-Y.; Wang, M.; Han, X.; Wang, S. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J. Med. Chem., 2019, 62(2), 448-466. doi: 10.1021/acs.jmedchem.8b00909 PMID: 30525597
  62. Yang, J.; Li, Y.; Aguilar, A.; Liu, Z.; Yang, C-Y.; Wang, S. Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: A cautionary tale in the design of PROTAC degraders. J. Med. Chem., 2019, 62(21), 9471-9487. doi: 10.1021/acs.jmedchem.9b00846 PMID: 31560543
  63. Wang, B.; Liu, J.; Tandon, I.; Wu, S.; Teng, P.; Liao, J.; Tang, W. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries. Eur. J. Med. Chem., 2021, 219113425 doi: 10.1016/j.ejmech.2021.113425 PMID: 33862513
  64. Doroshow, D.B.; Eder, J.P.; LoRusso, P.M. BET inhibitors: A novel epigenetic approach. Ann. Oncol., 2017, 28(8), 1776-1787. doi: 10.1093/annonc/mdx157 PMID: 28838216
  65. Stathis, A.; Bertoni, F. BET proteins as targets for anticancer treatment. Cancer Discov., 2018, 8(1), 24-36. doi: 10.1158/2159-8290.CD-17-0605 PMID: 29263030
  66. Zhou, B.; Hu, J.; Xu, F.; Chen, Z.; Bai, L.; Fernandez-Salas, E.; Lin, M.; Liu, L.; Yang, C-Y.; Zhao, Y.; McEachern, D.; Przybranowski, S.; Wen, B.; Sun, D.; Wang, S. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem., 2018, 61(2), 462-481. doi: 10.1021/acs.jmedchem.6b01816 PMID: 28339196
  67. Bai, L.; Zhou, B.; Yang, C-Y.; Ji, J.; McEachern, D.; Przybranowski, S.; Jiang, H.; Hu, J.; Xu, F.; Zhao, Y.; Liu, L.; Fernandez-Salas, E.; Xu, J.; Dou, Y.; Wen, B.; Sun, D.; Meagher, J.; Stuckey, J.; Hayes, D.F.; Li, S.; Ellis, M.J.; Wang, S. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res., 2017, 77(9), 2476-2487. doi: 10.1158/0008-5472.CAN-16-2622 PMID: 28209615
  68. Jiang, F.; Wei, Q.; Li, H.; Li, H.; Cui, Y.; Ma, Y.; Chen, H.; Cao, P.; Lu, T.; Chen, Y. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg. Med. Chem., 2020, 28(1)115181 doi: 10.1016/j.bmc.2019.115181 PMID: 31767403
  69. Carpenter, R.L.; Lo, H-W. STAT3 Target genes relevant to human cancers. Cancers (Basel), 2014, 6(2), 897-925. doi: 10.3390/cancers6020897 PMID: 24743777
  70. Chai, E.Z.P.; Shanmugam, M.K.; Arfuso, F.; Dharmarajan, A.; Wang, C.; Kumar, A.P.; Samy, R.P.; Lim, L.H.K.; Wang, L.; Goh, B.C.; Ahn, K.S.; Hui, K.M.; Sethi, G. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol. Ther., 2016, 162, 86-97. doi: 10.1016/j.pharmthera.2015.10.004 PMID: 26478441
  71. Zhou, H.; Bai, L.; Xu, R.; Zhao, Y.; Chen, J.; McEachern, D.; Chinnaswamy, K.; Wen, B.; Dai, L.; Kumar, P.; Yang, C-Y.; Liu, Z.; Wang, M.; Liu, L.; Meagher, J.L.; Yi, H.; Sun, D.; Stuckey, J.A.; Wang, S. Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein. J. Med. Chem., 2019, 62(24), 11280-11300. doi: 10.1021/acs.jmedchem.9b01530 PMID: 31747516
  72. Bai, L.; Zhou, H.; Xu, R.; Zhao, Y.; Chinnaswamy, K.; McEachern, D.; Chen, J.; Yang, C.Y.; Liu, Z.; Wang, M.; Liu, L.; Jiang, H.; Wen, B.; Kumar, P.; Meagher, J.L.; Sun, D.; Stuckey, J.A.; Wang, S. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell, 2019, 36(5), 498-511.e17. doi: 10.1016/j.ccell.2019.10.002 PMID: 31715132
  73. Zhou, H.; Bai, L.; Xu, R.; McEachern, D.; Chinnaswamy, K.; Li, R.; Wen, B.; Wang, M.; Yang, C-Y.; Meagher, J.L.; Sun, D.; Stuckey, J.A.; Wang, S. SD-91 as a potent and selective STAT3 degrader capable of achieving complete and long-lasting tumor regression. ACS Med. Chem. Lett., 2021, 12(6), 996-1004. doi: 10.1021/acsmedchemlett.1c00155 PMID: 34141084
  74. Bertoli, C.; Skotheim, J.M.; de Bruin, R.A.M. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol., 2013, 14(8), 518-528. doi: 10.1038/nrm3629 PMID: 23877564
  75. Ishoey, M.; Chorn, S.; Singh, N.; Jaeger, M.G.; Brand, M.; Paulk, J.; Bauer, S.; Erb, M.A.; Parapatics, K.; Müller, A.C.; Bennett, K.L.; Ecker, G.F.; Bradner, J.E.; Winter, G.E. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem. Biol., 2018, 13(3), 553-560. doi: 10.1021/acschembio.7b00969 PMID: 29356495
  76. Sancho, M.; Leiva, D.; Lucendo, E.; Orzáez, M. Understanding MCL1: From cellular function and regulation to pharmacological inhibition. FEBS J., 2021. febs.16136. doi: 10.1111/febs.16136 PMID: 34310025
  77. Widden, H.; Placzek, W.J. The multiple mechanisms of MCL1 in the regulation of cell fate. Commun. Biol., 2021, 4(1), 1029. doi: 10.1038/s42003-021-02564-6 PMID: 34475520
  78. Papatzimas, J.W.; Gorobets, E.; Maity, R.; Muniyat, M.I.; MacCallum, J.L.; Neri, P.; Bahlis, N.J.; Derksen, D.J. From inhibition to degradation: Targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1). J. Med. Chem., 2019, 62(11), 5522-5540. doi: 10.1021/acs.jmedchem.9b00455 PMID: 31117518
  79. Spillantini, M.G.; Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol., 2013, 12(6), 609-622. doi: 10.1016/S1474-4422(13)70090-5 PMID: 23684085
  80. Kovacs, G.G. Invited review: Neuropathology of tauopathies: Principles and practice. Neuropathol. Appl. Neurobiol., 2015, 41(1), 3-23. doi: 10.1111/nan.12208 PMID: 25495175
  81. Silva, M.C.; Ferguson, F.M.; Cai, Q.; Donovan, K.A.; Nandi, G.; Patnaik, D.; Zhang, T.; Huang, H.T.; Lucente, D.E.; Dickerson, B.C.; Mitchison, T.J.; Fischer, E.S.; Gray, N.S.; Haggarty, S.J. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. eLife, 2019, 8, 8. doi: 10.7554/eLife.45457 PMID: 30907729
  82. Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 2012, 16(1), 15-31. doi: 10.1517/14728222.2011.648617 PMID: 22239438
  83. Leonetti, A.; Sharma, S.; Minari, R.; Perego, P.; Giovannetti, E.; Tiseo, M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer, 2019, 121(9), 725-737. doi: 10.1038/s41416-019-0573-8 PMID: 31564718
  84. He, K.; Zhang, Z.; Wang, W.; Zheng, X.; Wang, X.; Zhang, X. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. Bioorg. Med. Chem. Lett., 2020, 30(12)127167 doi: 10.1016/j.bmcl.2020.127167 PMID: 32317208
  85. Xie, S.; Sun, Y.; Liu, Y.; Li, X.; Li, X.; Zhong, W.; Zhan, F.; Zhu, J.; Yao, H.; Yang, D-H.; Chen, Z-S.; Xu, J.; Xu, S. Development of alectinib-based PROTACs as novel potent degraders of anaplastic lymphoma kinase (ALK). J. Med. Chem., 2021, 64(13), 9120-9140. doi: 10.1021/acs.jmedchem.1c00270 PMID: 34176264
  86. Hallberg, B.; Palmer, R.H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat. Rev. Cancer, 2013, 13(10), 685-700. doi: 10.1038/nrc3580 PMID: 24060861
  87. Shaw, A.T.; Engelman, J.A. ALK in lung cancer: Past, present, and future. J. Clin. Oncol., 2013, 31(8), 1105-1111. doi: 10.1200/JCO.2012.44.5353 PMID: 23401436
  88. Lin, J.J.; Riely, G.J.; Shaw, A.T. Targeting ALK: Precision medicine takes on drug resistance. Cancer Discov., 2017, 7(2), 137-155. doi: 10.1158/2159-8290.CD-16-1123 PMID: 28122866

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bentham Science Publishers